NICE’s Cost-Effectiveness Range: Should It Be Lowered?

PharmacoEconomics - United Kingdom
doi 10.1007/s40273-014-0158-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC


Related search